Capmatinib, a drug targeting the MET tyrosine kinase receptor

Capmatinib is an innovative drug whose main target is the MET (mesenchymal epidermal transforming factor) tyrosine kinase receptor. METThe signaling pathway plays a pivotal role in cell growth, migration, survival, and angiogenesis. However, once the MET gene is mutated or amplified, it will trigger abnormal activation of signaling pathways and provide a "breeding ground" for the proliferation and metastasis of cancer cells.

The "unique secret" of Capmatinib is that it can precisely inhibit the activity of MET kinase, thereby blocking this abnormal signaling pathway and achieving significant effects in treating cancer. It is specifically targeted at patients with non-small cell lung cancer (NSCLC) who carry METex14 skipping mutations. Such mutations can lead to overexpression or enhanced function of the MET protein, disrupting the normal regulatory mechanism of cells and causing cancer. It is worth noting that METex14 skipping mutations account for about 3%-4% of NSCLC patients, and often respond poorly to traditional chemotherapy and immunotherapy, so targeted drug treatment is particularly important.

Not only that, capmatinib has also shown excellent efficacy against certain MET amplified and overexpressed tumors. In these cases, abnormal activity of the MET signaling pathway can cause cancer cells to become more aggressive and drug-resistant. Capmatinib provides new treatment options for these patients by selectively inhibiting these abnormal signals.

Capmatinib binds closely to METtyrosine kinase, inhibits its kinase activity, and then blocks the downstream signaling pathways related to MET, such as PI3K/AKT and RAS/MAPK. These signaling pathways play crucial roles in cell proliferation and survival. By inhibiting the excessive activation of these signaling pathways, capmatinib effectively reduces the proliferation, migration and angiogenesis of cancer cells, while promoting cell apoptosis.

As the first approved MET inhibitor, capmatinib fills the gap in the treatment of METex14 skipping mutation tumors and brings new hope to these patients. Clinical trial data show that capmatinib has a high overall response rate and durable response. In addition, studies have also shown that capmatinib also has certain efficacy in some patients with MET amplification or overexpression, which indicates that its scope of application is expected to be further expanded.

xa0

Reference materials

Official website of Novartis: https://www.novartis.com